Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden

View ORCID ProfileXaquin Castro Dopico, Sandra Muschiol, Murray Christian, View ORCID ProfileLeo Hanke, View ORCID ProfileDaniel J. Sheward, View ORCID ProfileNastasiya F. Grinberg, View ORCID ProfileGordana Bogdanovic, View ORCID ProfileGerald M. Mcinerney, Tobias Allander, View ORCID ProfileChris Wallace, View ORCID ProfileBen Murrell, View ORCID ProfileJan Albert, View ORCID ProfileGunilla B. Karlsson Hedestam
doi: https://doi.org/10.1101/2020.12.24.20248821
Xaquin Castro Dopico
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xaquin Castro Dopico
  • For correspondence: xaquin.castro.dopico@ki.se
Sandra Muschiol
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murray Christian
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo Hanke
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leo Hanke
Daniel J. Sheward
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel J. Sheward
Nastasiya F. Grinberg
3Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge CB2 0AW, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nastasiya F. Grinberg
Gordana Bogdanovic
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gordana Bogdanovic
Gerald M. Mcinerney
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gerald M. Mcinerney
Tobias Allander
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Wallace
3Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge CB2 0AW, UK
4MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge CB2 0SR, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chris Wallace
Ben Murrell
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ben Murrell
  • For correspondence: xaquin.castro.dopico@ki.se
Jan Albert
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jan Albert
  • For correspondence: xaquin.castro.dopico@ki.se
Gunilla B. Karlsson Hedestam
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gunilla B. Karlsson Hedestam
  • For correspondence: xaquin.castro.dopico@ki.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Structured abstract

Objectives As Sweden did not enforce social lockdown in response to the pandemic, it is critical to establish seropositivity to SARS-CoV-2 in healthy, active adults – here represented by blood donors and pregnant women. Random sampling was carried out in Stockholm, the country’s most populous region, and the study ran from virus emergence (March 2020) until the end of 2020, shortly prior to the first round of vaccinations, allowing for an estimate of population seropositivity in response to natural infection.

Design In this cross-sectional prospective study, otherwise-healthy blood donors (n=2,100) and pregnant women (n=2,000) were sampled at random for consecutive weeks (at three intervals) between 14th March and 11th December 2020. Sera from all participants and a large cohort of historical controls (n=595) were screened for IgG responses against the SARS-CoV-2 spike (S) trimer and the receptor-binding domain (RBD). As a complement to standard approaches to analyze the data, a probabilistic Bayesian approach that assigns likelihood of past infection was used to analyze the population data. The study was carried out in accordance with Swedish Ethical Review Authority registration no. 2020-01807.

Setting Healthy participant samples were selected from their respective pools at random through the Karolinska University Hospital.

Participants None of the participants were symptomatic at the time of sampling and none had previously been hospitalized for COVID-19. No additional metadata was available from the samples.

Results Blood donors and pregnant women showed a similar seroprevalence. After a steep rise at the start of the pandemic, the seroprevalence trajectory increased steadily in approach to the winter second-wave of infections, approaching 15% of all individuals surveyed by 11th December 2020. Importantly, 96% of antibody-positive healthy donors screened (n=56) developed neutralizing antibody responses at titers comparable to or higher than those observed in clinical trials of SARS-CoV-2 spike mRNA vaccination, supporting that mild infection engenders a competent B cell response.

Conclusions In agreement with currently rising COVID-19 cases and ICU occupancy during a second winter wave of infections, these data demonstrate that the metropolitan Stockholm area was far from herd immunity nine months after the outbreak, with approximately one-in-six persons in the examined cohort seropositive for SARS-CoV-2.

General abstract Public health strategies to contain the pandemic continue to vary markedly across the world. In Sweden, compared to most advanced economies, social restrictions have primarily relied upon voluntary adherence to a set of recommendations and strict lockdowns have not been enforced. To better understand the development of humoral immunity to SARS-CoV-2 in the Stockholm population before the start of mass vaccinations, healthy blood donors and pregnant women (n=4,100) were sampled at random between 14th March-11th December 2020. All individuals (n=200/sampling week) were screened for anti-SARS-CoV-2 spike (S) trimer- and RBD-specific IgG responses with highly sensitive and specific ELISA assays, and the results were compared with those from historical controls (n=595). Data were modelled using a probabilistic Bayesian framework that considered individual responses to both antigens. We found that after a steep rise at the start of the pandemic, the seroprevalence trajectory increased steadily in approach to the winter second-wave of infections, approaching 15% of all individuals surveyed by 11th December. In agreement with the high transmission rate observed in the Stockholm area, seroprevalence in this cohort of active adults increased during the 9 months from the start of the outbreak, but was far from that required for herd immunity at the end of 2020.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We would like to thank the study participants and attending clinical teams. Funding for this work was provided by a Distinguished Professor grant from the Swedish Research Council (agreement 2017-00968) and the National Institutes of Health, USA (agreement 400 SUM1A44462-02) awarded to GKH. CW received funding from the Wellcome Trust (WT107881) and Medical Research Council, UK (MC_UP_1302/5). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was carried out in accordance with Swedish Ethical Review Authority registration no. 2020-01807.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data generated as part of the study, along with custom code for statistical analyses, is openly available via our GitHub repositories: https://github.com/MurrellGroup/DiscriminativeSeroprevalence/ and https://github.com/chr1swallace/seroprevalence-paper.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 26, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden
Xaquin Castro Dopico, Sandra Muschiol, Murray Christian, Leo Hanke, Daniel J. Sheward, Nastasiya F. Grinberg, Gordana Bogdanovic, Gerald M. Mcinerney, Tobias Allander, Chris Wallace, Ben Murrell, Jan Albert, Gunilla B. Karlsson Hedestam
medRxiv 2020.12.24.20248821; doi: https://doi.org/10.1101/2020.12.24.20248821
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden
Xaquin Castro Dopico, Sandra Muschiol, Murray Christian, Leo Hanke, Daniel J. Sheward, Nastasiya F. Grinberg, Gordana Bogdanovic, Gerald M. Mcinerney, Tobias Allander, Chris Wallace, Ben Murrell, Jan Albert, Gunilla B. Karlsson Hedestam
medRxiv 2020.12.24.20248821; doi: https://doi.org/10.1101/2020.12.24.20248821

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4815)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5282)
  • Intensive Care and Critical Care Medicine (326)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (111)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (438)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (128)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (769)
  • Public and Global Health (1799)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)